Novo Nordisk (NVO): buy, hold or sell?
Genomics & AI-Health. One systematic signal, updated after every US close, with the exact prices to act at.
NVO has a live Hesper Atlas signal, refreshed after every US close. The current state and the full trade plan (exact buy / add / trim / sell prices) are in the app; a free account shows three full stock pages a day, no card required.
On held-out data the engine never trained on, the NVO engine returned +15.6% a year versus +16% buying and holding, with a worst drop of −24.3% versus −74.7% (after costs, next-day fills, 2026-07-07 evaluation).
The public ledger lists 1 recent closed NVO signals (1 ended in profit), regenerated nightly from end-of-day data, losers included.
What the engine did on NVO, honestly
Closed signals on NVO, from the public ledger
| Entry | Price | Exit | Price | Return | Days |
|---|---|---|---|---|---|
| 2022-11-09 | $57.08 | 2024-07-30 | $129.23 | +130.9% | 629 |
Held-out numbers: the engine is tuned on the earlier part of this name's history and scored on the last 40% it never trained on, after costs, next-day fills. Backtested, not live. Ledger rows are BUY-to-SELL round trips regenerated nightly from end-of-day data; losers stay listed. Method on the methodology page, every name's ledger on the track record page. Hesper Atlas is an educational publication with one systematic signal per name, identical for everyone. It is not financial advice and does not know your situation.
More names in Genomics & AI-Health
Each carries the same daily buy / hold / sell signal. All 155 tracked names are on the stocks index, grouped by theme.